ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for West Virginia's MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 2008
Meetings & Education
Abstract Achievement Awards
Financial Advocacy & Patient Assistance
WVOS Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
WV Health Plans
National Professional Organizations
WVOS Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
CMS Assigns New J-Codes for Rituxan and Rituxan Hycela
Effective January 1, 2019, the Centers for Medicare & Medicaid Services (CMS) has assigned new J-codes for Rituxan and Rituxan Hycela (Genentech, Inc.):
Injection, rituximab, 10 mg (replaces J-code J9310)
Injection, rituximab 10 mg and hyaluronidase
These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements.
Read more about the new J-codes for Rituxan and Rituxan Hycela here.